Merck Inc announces phase III KEYNOTE-826 trial met dual primary endpoints of overall survival and progression-free survival in patients with persistent, recurrent or metastatic cervical cancer

Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351 is brought to you by International Medical Information. For more details, visit

Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot accept responsibility for the authenticity of the content matter.

Copyright: The copyright of the material on this site rests with the author unless otherwise indicated. It is a breach of copyright to use any material from this site without prior written consent.